12 completed, 9 terminated, 3 unknown, 3 withdrawn. 31 Phase 2, 4 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 31 | Completed 12, Terminated 9, Unknown 3, Withdrawn 3, Not yet recruiting 2, Recruiting 2 |
| Phase 3 | 4 | Completed 2, Not yet recruiting 1, Terminated 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Thrombophilia: new trials by email Literature Review of Thrombophilia trials Research Report on Thrombophilia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Lumbrokinase DLBS1033 on D-Dimer, Interleukin-6, and Clinical Outcomes in Patients With Pneumonia and Sepsis Placebo Tablet(s), DLBS1033 - Pneumonia, Sepsis | Phase 2 | Completed | Universitas Sebelas Maret | 50 | 2025-08-14 | 2026-10-23 |
| BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases BCMA-CD19 CAR-T therapy - Systemic Lupus Erythematosus, Inflammatory Myopathy | Phase 2 | Recruiting | Peking University People's Hospital | 50 | 2024-12-26 | 2025-04-02 |
| Effect of Low Molecular Heparin on Pregnancy Outcome With Protein S Deficiency Enoxaparin, Aspirin - Pregnancy Related, Protein S Deficiency | Phase 2 | Not yet recruiting | Peking University People's Hospital | 48 | 2024-08-01 | 2024-08-01 |
| A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP) TAK-755 - Thrombotic Thrombocytopenic Purpura (TTP) | Phase 2 | Completed | Takeda | 29 | 2023-07-21 | 2026-06-17 |
| Aspirin for Prophylaxis of TTP Aspirin tablet, Placebo - Thrombotic Thrombocytopenic Purpura | Phase 2 / Phase 3 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 100 | 2022-10-01 | 2022-10-05 |
| Viscoelastic Testing Guided Tissue Plasminogen Activator Treatment in Acute Respiratory Failure Alteplase - Acute Respiratory Failure, Hypercoagulability | Phase 2 | Recruiting | South West Sydney Local Health District | 70 | 2022-05-18 | 2024-04-17 |
| SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations BMS-986414, BMS-986413 - SARS-CoV2 Infection, SARS-CoV-2 Acute Respiratory Disease | Phase 2 | Withdrawn | Imperial College Healthcare NHS Trust | 2021-11-29 | 2023-04-24 | |
| Antithrombin III in Infectious Disease Caused by COVID-19 Antithrombin III - Antithrombin III Deficiency, Covid19 | Phase 2 | Terminated | Enrique Ginzburg | 52 | 2021-07-06 | 2022-09-07 |
| Infusional Fluorouracil and Weekly Docetaxel for Gastric Cancer With Bone Marrow Involvement and DIC 5-fluorouracil, Docetaxel - Gastric Cancer, Bone Marrow Metastasis | Phase 2 | Completed | Sixth Affiliated Hospital, Sun Yat-sen University | 24 | 2021-01-15 | 2024-03-25 |
| Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia Romiplostim, Rituximab, Dexamethasone - Immune Thrombocytopenia, Thrombotic Thrombocytopenic Purpura | Phase 2 | Unknown | David Gomez Almaguer | 12 | 2020-11-01 | 2020-10-19 |
| The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations Aspirin 81 mg, Vitamin D - COVID, Vitamin D Deficiency | Phase 2 | Withdrawn | Louisiana State University Health Sciences Center in New Orleans | 2020-05-01 | 2021-12-27 | |
| A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) Caplacizumab (ALX-0081), Plasma exchange (PE), Corticosteroid treatment (Methylprednisolone or prednisolone) - Thrombotic Thrombocytopenic Purpura | Phase 2 / Phase 3 | Completed | Sanofi | 21 | 2019-10-21 | 2025-09-22 |
| Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) Placebo, SHP655, Standard of Care - Acquired Thrombotic Thrombocytopenic Purpura (aTTP) | Phase 2 | Completed | Shire | 28 | 2019-10-09 | 2022-12-01 |
| A Clinical Study of Anfibatide in Acquired Thrombotic Thrombocytopenic Purpura (TTP) Anfibatide, Placebos - Acquired Thrombotic Thrombocytopenic Purpura | Phase 2 | Unknown | Lee's Pharmaceutical Limited | 74 | 2019-07-01 | 2019-07-17 |
| Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer Atezolizumab, Bevacizumab - MSI, ColoRectal Cancer | Phase 2 | Terminated | Vall d'Hebron Institute of Oncology | 46 | 2017-11-24 | 2025-10-01 |
| IdeS in Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients IdeS (0.25 mg/kg), IdeS (0.50 mg/kg) - Purpura, Thrombotic Thrombocytopenic | Phase 2 | Terminated | Hansa Biopharma AB | 2 | 2016-09-01 | 2019-09-13 |
| Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura rituximab - Thrombotic Thrombocytopenic Purpura | Phase 2 | Completed | Washington University School of Medicine | 19 | 2012-08-01 | 2021-08-17 |
| Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) Caplacizumab, Placebo - Acquired Thrombotic Thrombocytopenic Purpura | Phase 2 | Completed | Ablynx, a Sanofi company | 75 | 2011-01-01 | 2023-04-04 |
| Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura rituximab - Thrombotic Thrombocytopenic Purpura | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 12 | 2010-05-01 | 2014-02-27 |
| An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP) Lusutrombopag - Immune Thrombocytopenia | Phase 2 | Terminated | Shionogi | 19 | 2010-04-29 | 2021-02-26 |
Showing 20 of 31. Sign in to see all of them.
Purpura, Thrombotic Thrombocytopenic (20) · Disseminated Intravascular Coagulation (4) · Purpura, Thrombocytopenic, Idiopathic (4) · Thrombocytopenia (4) · Hematologic Diseases (3) · Antithrombin III Deficiency (2) · Blood Platelet Disorders (2) · COVID-19 (2) · Hemostatic Disorders (2) · Sepsis (2) · Activated Protein C Resistance (1) · Anemia, Hemolytic (1) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Antiphospholipid Syndrome (1)
Hemic and Lymphatic Diseases (31) · Blood Coagulation Disorders (29) · Hematologic Diseases (28) · Pathologic Processes (22) · Pathological Conditions, Signs and Symptoms (22) · Cytopenia (20) · Hemorrhage (20) · Purpura (20) · Purpura, Thrombocytopenic (20) · Signs and Symptoms (20) · Skin Manifestations (20) · Thrombotic Microangiopathies (19) · Blood Platelet Disorders (18) · Thrombocytopenia (16)
Rituximab (7) · Aspirin (3) · ARC 1779 (2) · Plasma Exchange (2) · caplacizumab (2) · lusutrombopag (2) · ADAMTS13 protein, human (1) · ART123 (1) · Adrenal Cortex Hormones (1) · Antithrombin III (1) · Bevacizumab (1) · DLBS 1033 (1) · Danazol (1) · Dexamethasone (1) · Docetaxel (1)
Archemix Corp. (2) · Peking University People's Hospital (2) · Shionogi (2) · Ablynx, a Sanofi company (1) · Artisan Pharma, Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · Baxalta now part of Shire (1) · David Gomez Almaguer (1) · Enrique Ginzburg (1) · Hamilton Health Sciences Corporation (1) · Hansa Biopharma AB (1) · Icahn School of Medicine at Mount Sinai (1) · Imperial College Healthcare NHS Trust (1) · Instituto Grifols, S.A. (1) · LEO Pharma (1)
United States (12) · United Kingdom (7) · Italy (5) · Austria (4) · Canada (4) · China (4) · Spain (4) · France (3) · Australia (2) · Belgium (2) · Germany (2) · Bulgaria (1) · Greece (1) · Indonesia (1) · Israel (1)
Anders Aneman (1) · Andy Peniket (1) · David Barth, MD (1) · Elaine M Majerus, MD, PhD (1) · Eldaa Putik Bunga Melati, MD (1) · Elisabeth Sonesson, PhD (1) · Enrique Ginzburg (1) · Frank H Lau, MD (1) · Gail Rock, MD (1) · Ilan Shapira, M.D. (1) · James B Bussel, M.D. (1)
PMID 12353309, PMID 15389904, PMID 20058208, PMID 21636861, PMID 22475545, PMID 23279219, PMID 23470153, PMID 23616916, PMID 24802773, PMID 26863353, PMID 27307776, PMID 27643485, PMID 30488420, PMID 30957581, PMID 33881463, PMID 36346044, PMID 36427162, PMID 36765421, PMID 37489818, PMID 39095866, PMID 39911044
2016 (1), 2018 (1), 2023 (1), U54HL112303 (1)